Month: May 2023

P R E S S  R E L E A S EStockholm, May 12, 2023 Flat revenue growth (2 percent) in a challenging quarter January 1 – March 31, 2023 • Net sales amounted to MSEK 579 (524). Adjusted for changes in foreign exchange rates, net sales increased 2 percent, whereof all organic.• Operating profit (EBITA) decreased 16 percent to MSEK 47 (56).• Operating margin (EBITA margin) was 8.2 (10.8) percent.• Profit after tax decreased 21 percent to MSEK 23 (29).• Earnings per share decreased 21 percent to SEK 1.17 (1.49). CEO comments, Jessica Skon“To further reduce costs, we have stopped recruitment since the fourth quarter of 2022 and are implementing additional efficiency programs amounting to annual cost savings of approximately 60 MSEK. The cost benefits are expected to be fully realized in the second half of 2023.” Outlook for 2023“We...

High activity despite challenging market conditions AKVA group delivered revenue for Q1 of MNOK 874 (849), an increase of 3% compared to Q1 2022. EBITDA decreased from MNOK 69 (excluding one-time gain of MNOK 33 from sale of shares in Atlantis Subsea Farming AS) in Q1 2022 to MNOK 59 in Q1 2023. Acceptable order intake of MNOK 1,170 (1,048) in Q1 and order backlog of BNOK 2 at the end of March 2023. Award of new RAS contract with NOAP for next 4,000 tonnes (phase 2). Estimated contract value of MEUR 40. Market for post smolt project in Norway still on hold due to the resource tax. Commercial breakthrough of deep sea farming concepts in April The activity in the first quarter of 2023 was high and above last year. Overall, the order intake was sound with the newly awarded RAS contract for NOAP as the largest contributor. Profitability...

In the first quarter of 2023, Mendus continued on the path set out by the key progress realized at the end of 2022. The Phase 2 monotherapy proof-of-concept data from the ADVANCE II trial presented last December at the American Society for Hematology conference support the continued clinical development of vididencel (DCP-001) in combination with standard of care, for which we are preparing the next steps. In the meantime, we continue with the in-depth analysis of the immunomonitoring data collected as part of the ADVANCE II trial. The data teach us a lot about the way vididencel stimulates the immune system and which immunological parameters are important to improve immune control or even achieve complete elimination of residual disease. The successful initial read-outs on safety and feasibility of the ALISON Phase 1 trial studying vididencel...

 To        Nasdaq Copenhagen A/Sand the press12 May 2023Nykredit today announces its Q1 Interim Reports 2023 of: Nykredit A/S, CVR no 12 71 92 48 Nykredit Realkredit A/S, CVR no 12 71 92 80  Michael Rasmussen, Group Chief Executive, comments on the Q1 Interim Report 2023:Nykredit has today presented its best-ever Q1 results with profit after tax of DKK 2,799 million. Naturally, this is highly satisfactory. We already raised our guidance for profit for the year by DKK 1 billion and now expect a profit after tax of DKK 9-10 billion.First quarter was driven by strong business growth and continued increases in the number of new customers across the Group. Nykredit Bank reported continued growth in bank lending, particularly to our largest corporate clients. Also Wealth Management performed well. I am proud that Nykredit maintains...

Press Release 12 May 2023 – N° 9 First quarter 2023 results under IFRS 17 SCOR generates a net income of EUR 311 million and significantly increases its Economic Value1 in Q1 2023Insurance revenue of EUR 3,926 million in Q1 2023, down 4.2%2 compared with Q1 2022 Group net income of EUR 311 million in Q1 2023, compared with a net loss of EUR -35 million in Q1 2022Group Economic Value under IFRS 17 of EUR 9,784 million as of 31 March 2023, up 9.4%3 (+6.3%3 on a constant interest and exchange rate basis) compared with 31 December 2022, implying an Economic Value per share of EUR 54 (vs. EUR 50 as of 31 December 2022) Estimated Group solvency ratio of 219%4 as of 31 March 2023, at the upper end of the optimal solvency rangeSCOR SE’s Board of Directors met on 11 May 2023, under the chairmanship of Denis Kessler, to approve...

HighlightsHarvest volume of 15,357 tonnes (16,916 tonnes) Operational EBIT in the quarter of NOK 385 million (NOK 453 million), with operational EBIT/kg of NOK 25.1 (26.8) Salmon market remains strong, supporting earnings Harvest volume above guidance due to advanced harvesting related to biological challenges. Increasing smolt release to compensate and rebuild biomass  Newfoundland developing according to plan 81% of harvested volume in the quarter was ASC certified Dividend proposal of NOK 4.5 per share based on a record high 2022 result, subject to approval by the Annual General Meeting in June 2023 Expect harvest of 21,300 tonnes in Q2 2023 and 80,000 tonnes for the year 2023Financial results Operational EBIT for Grieg Seafood was NOK 385 million in the first quarter of 2023, compared to NOK 453 million in the corresponding...